A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study
ObjectiveTo analyze real-world evidence on work productivity and daily activity impairment (WPAI) and health-related quality of life (HRQoL) in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) patients treated with golimumab in Austria.MethodsThis was a prosp...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.881943/full |
| _version_ | 1818554497558904832 |
|---|---|
| author | Christian Dejaco Christian Dejaco Thomas Mueller Omid Zamani Ulrike Kurtz Stefan Egger Johannes Resch-Passini Anna Totzauer Babak Yazdani-Biuki Thomas Schwingenschloegl Peter Peichl Angelika Kraus Gerhard W. Naerr |
| author_facet | Christian Dejaco Christian Dejaco Thomas Mueller Omid Zamani Ulrike Kurtz Stefan Egger Johannes Resch-Passini Anna Totzauer Babak Yazdani-Biuki Thomas Schwingenschloegl Peter Peichl Angelika Kraus Gerhard W. Naerr |
| author_sort | Christian Dejaco |
| collection | DOAJ |
| description | ObjectiveTo analyze real-world evidence on work productivity and daily activity impairment (WPAI) and health-related quality of life (HRQoL) in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) patients treated with golimumab in Austria.MethodsThis was a prospective, non-interventional, multi-center study conducted in RA, PsA and axSpA patients initiating golimumab between April 2016 and May 2020 in 40 centers in Austria. WPAI, HRQoL (RAQoL, ankylosing spondylitis (AS)QoL and PsAQoL) questionnaires and disease activity (Clinical Disease Activity Index, CDAI, in RA and PsA; Bath Ankylosing Spondylitis Disease Activity Index, BASDAI, in axSpA) were assessed at baseline and months 3, 6, 12, 18, and 24. Association between WPAI and disease activity was tested using linear regression.ResultsWe enrolled 233 patients (RA, n = 95; axSpA, n = 69; PsA, n = 69), 110 patients were followed up to month 24. Mean age was 50.2 ± 14.2 years; 64% were female. Disease activity decreased from baseline to month 24 (RA: CDAI −24.3 ± 13.5; axSpA: BASDAI −4.4 ± 2.1, and PsA: CDAI −21.7 ± 8.5, p < 0.0001, each). Total work productivity impairment (TWPI), activity impairment and presenteeism subscores continuously decreased throughout month 24 in all indications: RA (−58.3 ± 23%, −62.6 ± 23.8% and −61.7 ± 23.3%, respectively as compared to baseline; p < 0.0001, each), axSpA (−34.4 ± 38.3%, p = 0.0117; −60.9 ± 25.9%, and −43.8 ± 26.6%, respectively, p ≤ 0.0001 both) and PsA (−35.8 ± 43.7%, p = 0.0186; −52.3 ± 25.4%, p < 0.0001; and −43.3 ± 33.5%, p = 0.0007, respectively). Absenteeism scores decreased only in RA patients (−9.2 ± 24.9%, p = 0.0234). HRQoL improved between baseline and month 24 (RAQoL: −12.6 ± 7.5; ASQoL: −8.0 ± 4.3; PsAQoL; −8.3 ± 6.4, p < 0.0001, each). TWPI, presenteeism and activity impairment strongly associated with disease activity throughout the study.ConclusionsThis real-world study confirms the benefit of golimumab on work productivity/daily activity impairment in Austrian RA, PsA, and axSpA patients. |
| first_indexed | 2024-12-12T09:40:27Z |
| format | Article |
| id | doaj.art-5f031be76ec64512922a61626a12ddf1 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-12T09:40:27Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-5f031be76ec64512922a61626a12ddf12022-12-22T00:28:34ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.881943881943A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE StudyChristian Dejaco0Christian Dejaco1Thomas Mueller2Omid Zamani3Ulrike Kurtz4Stefan Egger5Johannes Resch-Passini6Anna Totzauer7Babak Yazdani-Biuki8Thomas Schwingenschloegl9Peter Peichl10Angelika Kraus11Gerhard W. Naerr12Department of Rheumatology, Medical University of Graz, Graz, AustriaDepartment of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, ItalyPrivate Office, Graz, AustriaRheuma Zentrum Favoriten, Vienna, AustriaRheuma Praxis Dr. Kurtz, Gleisdorf, AustriaOrdination Gesundheitsquadrat, Vienna, AustriaRheuma-Zentrum Wien-Oberlaa GmbH, Vienna, AustriaPrivate Office Dr. Anna Totzauer, Gmünd, AustriaDr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fürstenfeld, Austria0Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria1Private Office Prim. Univ. Doz. Dr. Peter Peichl, Vienna, Austria2Private Office Dr. Angelika Kraus, Melk, Austria3MSD Ges.m.b.H., The Icon Vienna, Vienna, AustriaObjectiveTo analyze real-world evidence on work productivity and daily activity impairment (WPAI) and health-related quality of life (HRQoL) in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) patients treated with golimumab in Austria.MethodsThis was a prospective, non-interventional, multi-center study conducted in RA, PsA and axSpA patients initiating golimumab between April 2016 and May 2020 in 40 centers in Austria. WPAI, HRQoL (RAQoL, ankylosing spondylitis (AS)QoL and PsAQoL) questionnaires and disease activity (Clinical Disease Activity Index, CDAI, in RA and PsA; Bath Ankylosing Spondylitis Disease Activity Index, BASDAI, in axSpA) were assessed at baseline and months 3, 6, 12, 18, and 24. Association between WPAI and disease activity was tested using linear regression.ResultsWe enrolled 233 patients (RA, n = 95; axSpA, n = 69; PsA, n = 69), 110 patients were followed up to month 24. Mean age was 50.2 ± 14.2 years; 64% were female. Disease activity decreased from baseline to month 24 (RA: CDAI −24.3 ± 13.5; axSpA: BASDAI −4.4 ± 2.1, and PsA: CDAI −21.7 ± 8.5, p < 0.0001, each). Total work productivity impairment (TWPI), activity impairment and presenteeism subscores continuously decreased throughout month 24 in all indications: RA (−58.3 ± 23%, −62.6 ± 23.8% and −61.7 ± 23.3%, respectively as compared to baseline; p < 0.0001, each), axSpA (−34.4 ± 38.3%, p = 0.0117; −60.9 ± 25.9%, and −43.8 ± 26.6%, respectively, p ≤ 0.0001 both) and PsA (−35.8 ± 43.7%, p = 0.0186; −52.3 ± 25.4%, p < 0.0001; and −43.3 ± 33.5%, p = 0.0007, respectively). Absenteeism scores decreased only in RA patients (−9.2 ± 24.9%, p = 0.0234). HRQoL improved between baseline and month 24 (RAQoL: −12.6 ± 7.5; ASQoL: −8.0 ± 4.3; PsAQoL; −8.3 ± 6.4, p < 0.0001, each). TWPI, presenteeism and activity impairment strongly associated with disease activity throughout the study.ConclusionsThis real-world study confirms the benefit of golimumab on work productivity/daily activity impairment in Austrian RA, PsA, and axSpA patients.https://www.frontiersin.org/articles/10.3389/fmed.2022.881943/fullsocio economichealth economicbiologicalsrheumatoid arthritispsoriatic arthritisankylosing spondylitis |
| spellingShingle | Christian Dejaco Christian Dejaco Thomas Mueller Omid Zamani Ulrike Kurtz Stefan Egger Johannes Resch-Passini Anna Totzauer Babak Yazdani-Biuki Thomas Schwingenschloegl Peter Peichl Angelika Kraus Gerhard W. Naerr A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study Frontiers in Medicine socio economic health economic biologicals rheumatoid arthritis psoriatic arthritis ankylosing spondylitis |
| title | A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study |
| title_full | A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study |
| title_fullStr | A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study |
| title_full_unstemmed | A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study |
| title_short | A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study |
| title_sort | prospective study to evaluate the impact of golimumab therapy on work productivity and activity and quality of life in patients with rheumatoid arthritis psoriasis arthritis and axial spondyloarthritis in a real life setting in austria the go active study |
| topic | socio economic health economic biologicals rheumatoid arthritis psoriatic arthritis ankylosing spondylitis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.881943/full |
| work_keys_str_mv | AT christiandejaco aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT christiandejaco aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT thomasmueller aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT omidzamani aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT ulrikekurtz aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT stefanegger aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT johannesreschpassini aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT annatotzauer aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT babakyazdanibiuki aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT thomasschwingenschloegl aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT peterpeichl aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT angelikakraus aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT gerhardwnaerr aprospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT christiandejaco prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT christiandejaco prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT thomasmueller prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT omidzamani prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT ulrikekurtz prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT stefanegger prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT johannesreschpassini prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT annatotzauer prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT babakyazdanibiuki prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT thomasschwingenschloegl prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT peterpeichl prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT angelikakraus prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy AT gerhardwnaerr prospectivestudytoevaluatetheimpactofgolimumabtherapyonworkproductivityandactivityandqualityoflifeinpatientswithrheumatoidarthritispsoriasisarthritisandaxialspondyloarthritisinareallifesettinginaustriathegoactivestudy |